| pubmed-article:20347295 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0034289 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C1373120 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:20347295 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:20347295 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:20347295 | pubmed:dateCreated | 2010-4-20 | lld:pubmed |
| pubmed-article:20347295 | pubmed:abstractText | Novel 2-aryalkylthio-4-amino-6-benzylpyrimidines (3a-i), which can be considered as S-DABO and TMC-125 analogue hybrid molecules, have been designed and synthesized as inhibitors of HIV-1 RT. The results clearly indicated that the changes at the N(3)/C(4) position of pyrimidine ring could affect the hydrogen bonds strength and number between N(3)/C(4) and the Lys101 residue which are indispensable for anti-HIV-1 RT activity. The biological activity results are also in accordance with the docking study. | lld:pubmed |
| pubmed-article:20347295 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20347295 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347295 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20347295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347295 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347295 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20347295 | pubmed:month | May | lld:pubmed |
| pubmed-article:20347295 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:RaiK CKC | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:GuoYingY | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:ZhangLiangren... | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:LiuChangC | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:ZhangSiweiS | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:WangXiaoweiX | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:LiuJunyiJ | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:HsuS-BSB | lld:pubmed |
| pubmed-article:20347295 | pubmed:author | pubmed-author:ZhangJianfang... | lld:pubmed |
| pubmed-article:20347295 | pubmed:copyrightInfo | 2009 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20347295 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20347295 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20347295 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20347295 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20347295 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20347295 | pubmed:pagination | 3003-5 | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:meshHeading | pubmed-meshheading:20347295... | lld:pubmed |
| pubmed-article:20347295 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20347295 | pubmed:articleTitle | Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. | lld:pubmed |
| pubmed-article:20347295 | pubmed:affiliation | College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, PR China. | lld:pubmed |
| pubmed-article:20347295 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20347295 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20347295 | lld:chembl |
